Key Insights

Highlights

Success Rate

83% trial completion

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 49/100

Termination Rate

15.4%

2 terminated out of 13 trials

Success Rate

83.3%

-3.2% vs benchmark

Late-Stage Pipeline

23%

3 trials in Phase 3/4

Results Transparency

40%

4 of 10 completed with results

Key Signals

4 with results83% success

Data Visualizations

Phase Distribution

12Total
P 1 (3)
P 2 (6)
P 3 (3)

Trial Status

Completed10
Terminated2
Unknown1

Trial Success Rate

83.3%

Benchmark: 86.5%

Based on 10 completed trials

Clinical Trials (13)

Showing 13 of 13 trials
NCT03896958Unknown

The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)

NCT01958372Phase 1Completed

Radiation Therapy, Chemotherapy, and Soy Isoflavones in Treating Patients With Stage IIIA-IIIB Non-Small Cell Lung Cancer

NCT01557959Phase 2Completed

Docetaxel, Cisplatin, Pegfilgrastim, and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

NCT00368992Phase 2Completed

S0536: Cetuximab, Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients With Advanced Non-Small Cell Lung Cancer

NCT00049543Phase 3Completed

Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Removed by Surgery

NCT00118144Phase 2Completed

Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung Cancer

NCT00369551Phase 1Terminated

Bevacizumab, Paclitaxel, Carboplatin, and Radiation Therapy to the Chest in Treating Patients With Locally Advanced Non-Small Cell Lung Cancer

NCT00002852Phase 3Completed

Surgery With or Without Chemotherapy in Treating Patients With Stage I Non-small Cell Lung Cancer

NCT00040794Phase 2Completed

Combination Chemotherapy, Radiation Therapy, and Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer

NCT00029003Phase 2CompletedPrimary

Gefitinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

NCT00020709Phase 3Completed

Combination Chemotherapy and Radiation Therapy With or Without Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery

NCT00021060Phase 2Completed

Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer

NCT00042835Phase 1Terminated

Erlotinib and Radiation Therapy Plus Combination Chemotherapy in Treating Patients With Inoperable Stage III Non-Small Cell Lung Cancer

Showing all 13 trials

Research Network

Activity Timeline